MRE11 variants as predictive markers of radiotherapy response in muscle invasive bladder cancer

MRE11 variants as predictive markers of radiotherapy response in muscle invasive bladder cancer

Detalhes bibliográficos
Principais autores:	Teo, M, Snowden, H, Elliott, F, Morgan, J, Harland, M, Taylor, G, Bishop, D, Kiltie, A
Formato:	Journal article
Publicado em:	2012

Registros relacionados

Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer
por: Teo, M, et al.
Publicado em: (2014)

MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer.
por: Choudhury, A, et al.
Publicado em: (2010)

High MRE11 expression in muscle invasive bladder cancer is predictive of improved cause-specific survival following radical radiotherapy compared to surgery
por: Teo, T, et al.
Publicado em: (2010)

MRE11 as a predictive biomarker of outcome following radiotherapy in bladder cancer
por: Walker, AK, et al.
Publicado em: (2019)

Clinically relevant MRE11 variants in bladder cancer
por: Jevons, S
Publicado em: (2015)

MRE11A isoform expression associated with outcome following radiotherapy in muscle-invasive bladder cancer does not alter cell survival and DNA double-strand break repair following ionising radiation
por: Walker, AK, et al.
Publicado em: (2019)

Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer.
por: Choudhury, A, et al.
Publicado em: (2011)

No additional prognostic value for MRE11 in squamous cell carcinomas of the anus treated with chemo-radiotherapy
por: Walker, A, et al.
Publicado em: (2017)

Utility of bladder-sparing therapy vs radical cystectomy for muscle-invasive bladder cancer
por: Efstathiou, J, et al.
Publicado em: (2018)

A multicentre NCRI phase II study of hypofractionated conformal radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer
por: Choudhury, A, et al.
Publicado em: (2010)

Predictive biomarkers in muscle-invasive bladder cancer
por: Walker, A
Publicado em: (2017)

E3 ligase cIAP2 mediates downregulation of MRE11 and radiosensitization in response to HDAC inhibition in bladder cancer
por: Nicholson, J, et al.
Publicado em: (2017)

High-throughput DNA sequencing identifies novel CtIP (RBBP8) variants in muscle-invasive bladder cancer patients
por: Jevons, S, et al.
Publicado em: (2015)

Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future
por: Hermans, TJN, et al.
Publicado em: (2017)

Analysis of variants in DNA damage signalling genes in bladder cancer
por: Choudhury, A, et al.
Publicado em: (2008)

Contemporary patterns of multidisciplinary care in patients with muscle-invasive bladder cancer
por: Harshman, LC, et al.
Publicado em: (2017)

Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network
por: Zuiverloon, TCM, et al.
Publicado em: (2018)

Mouse models of muscle-invasive bladder cancer: Key considerations for clinical translation based on molecular subtypes
por: Ruan, J, et al.
Publicado em: (2018)

The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes.
por: Teo, M, et al.
Publicado em: (2012)

In vitro functional effects of XPC gene rare variants from bladder cancer patients.
por: Qiao, B, et al.
Publicado em: (2011)

Comparison of treatment outcome for radical surgery versus radical radiotherapy for invasive bladder cancer treated in a UK specialist treatment centre
por: Kotwal, S, et al.
Publicado em: (2007)

Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center.
por: Kotwal, S, et al.
Publicado em: (2008)

SPRTN protease-cleaved MRE11 decreases DNA repair and radiosensitises cancer cells
por: Na, J, et al.
Publicado em: (2021)

Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer
por: Ottley, EC, et al.
Publicado em: (2020)

THE HYPOXIC REGULATION OF FGFR3 IN NON MUSCLE INVASIVE BLADDER CANCER
por: Blick, C, et al.
Publicado em: (2011)

Ultrasound mediated gemcitabine delivery reduces the normal tissue toxicity of chemoradiation therapy in a muscle-invasive bladder cancer model
por: Ruan, J-L, et al.
Publicado em: (2021)

Papillary and muscle invasive bladder tumors with distinct genomic stability profiles have different DNA repair fidelity and KU DNA-binding activities.
por: Bentley, J, et al.
Publicado em: (2009)

Functional assays to determine the significance of two common XPC 3'UTR variants found in bladder cancer patients.
por: Qiao, B, et al.
Publicado em: (2011)

The management of non-muscle-invasive bladder cancer: A comparison of European and UK guidelines
por: Leiblich, A, et al.
Publicado em: (2018)

The impact of histological variants of urothelial carcinoma on clinical outcomes following trimodality bladder-sparing chemoradiation
por: Kiltie, A, et al.
Publicado em: (2017)

APE1 and XRCC1 protein expression levels predict cancer-specific survival following radical radiotherapy in bladder cancer.
por: Sak, S, et al.
Publicado em: (2005)

The polyAT, intronic IVS11-6 and Lys939Gln XPC polymorphisms are not associated with transitional cell carcinoma of the bladder.
por: Sak, S, et al.
Publicado em: (2005)

High levels of patient satisfaction in joint uro-oncology clinics to assist patient choice in early prostate cancer and muscle-invasive bladder cancer
por: Kiltie, A, et al.
Publicado em: (2018)

High levels of patient satisfaction in joint uro-oncology clinics to assist patient choice in early prostate cancer and muscle-invasive bladder cancer
por: Kiltie, A, et al.
Publicado em: (2018)

Tumor markers of bladder cancer : the schistosomal bladder tumors versus non-schistosomal bladder tumors.
por: Abdulamir, Ahmed Sahib, et al.
Publicado em: (2009)

Predictive Biomarkers for Gemcitabine as a Chemoradiosensitizer in Bladder Cancer
por: Kerr, M, et al.
Publicado em: (2012)

Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center: In regard to Kotwal et al. - In reply to Dr. Rosario et al.
por: Kiltie, A, et al.
Publicado em: (2008)

Numerical Study of Effects of Bladder Filling on Prostate Positioning In Radiotherapy
por: Krywonos, J, et al.
Publicado em: (2009)

p97/VCP inhibition causes excessive MRE11-dependent DNA end resection promoting cell killing after ionizing radiation
por: Kilgas, S, et al.
Publicado em: (2021)

Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer: Interventional procedures guidance [IPG628]
por: National Institute for Health and Care Excellence, CA, et al.
Publicado em: (2018)